Soliton Announces Positive Interim Clinical Trial Results with 27% Average Reduction in Scar Volume From Single Non-Invasive Treatment

Stock Information for Soliton Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Soliton Inc.

Soliton Initiates Significant Step Towards Commercialization
Soliton and Emphysys Enter Into a 3-year Development Agreement
Soliton Announces First Follow-up Visit Conducted in the Pivotal Cellulite Clinical Trial
Soliton Completes Treatment of All Patients in Pivotal Cellulite Trial
Soliton's Recent Positive Data Increases Potential Fibrotic Indications
Soliton to Announce Keloid Trial Data on October 25, 2019 and Host Webcast at 5:30PM ET to Discuss Results
Soliton's FDA Cleared RAP Device is Granted Two Additional Key Patents
Soliton Announces $6.25 Million Private Placement

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.